Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07547007 | Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma(BAPAMM) | recruiting | N/A | 86 | Centre Hospitalier Metropole SavoieOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548697 | A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 1 |
| Apr 23, 2026 |
| clinicaltrials |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03823534 | Post-Op Pain Control for Prophylactic Intramedullary Nailing. | recruiting | Phase 3 | 60 | St. Louis UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06386315 | Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma | recruiting | Phase 2 | 112 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | recruiting | Phase 2 | 65 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02726750 | Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05646576 | Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy(PEACE) | recruiting | N/A | 90 | Massachusetts General HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT04839003 | A Registry of AL Amyloidosis (ReAL)(ReAL) | recruiting | — | 5,000 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05640843 | A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | recruiting | N/A | 180 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06205953 | A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)(EUREKA) | recruiting | — | 400 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 6 | Apr 16, 2026 | clinicaltrials |
| NCT06383143 | Promoting Diagnosis and Management of AL in Italy (ProDigALIty)(ProDigALIty) | recruiting | — | 760 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06385652 | PET Imaging Study of 68Ga-NB381 in Multiple Myeloma | recruiting | Early Phase 1 | 30 | Peking University First HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06484777 | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma | recruiting | Phase 1 | 138 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05136807 | Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | recruiting | — | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05336383 | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | recruiting | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 4 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06145581 | Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma | recruiting | N/A | 25 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07032714 | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma(MAGENTA) | recruiting | Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07260812 | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04234022 | Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma | recruiting | — | 70 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05183854 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | recruiting | Phase 2 | 61 | University of UtahOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05361694 | Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions(TRANSFORMM) | recruiting | — | 1,000 | University of MiamiOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04300998 | Study of CAR-T Therapy in Older Patients | recruiting | — | 154 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06048250 | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514052 | Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study | recruiting | — | 127 | Shanxi Bethune HospitalOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06252792 | Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma | recruiting | — | 50 | FengYan JinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06536413 | ATRA and Carfilzomib in Plasma Cell Myeloma Patients(ATRA) | recruiting | Phase 1 / Phase 2 | 42 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07069751 | A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma(HiFi-MM) | recruiting | N/A | 62 | Ciceri FabioOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509086 | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia | recruiting | Phase 2 | 25 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05257018 | R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse | recruiting | Phase 2 | 83 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05862012 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | recruiting | Phase 1 | 200 | Ichnos Sciences SAINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT07030400 | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma | recruiting | — | 100 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07059650 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | recruiting | Phase 1 / Phase 2 | 150 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06536452 | Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects | recruiting | — | 50 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05898646 | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | recruiting | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2026source: clinicaltrials